Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape
By J. Tregoning, Katie E. Flight, Sophie Higham, Ziyin Wang, B. F. Pierce. Nature reviews. Immunology, 2021
998 citations recorded by the source corpus.
Where 2020 saw the development and testing of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has seen vaccine rollout in many countries. In this Progress article, we provide a snapshot of ongoing vaccine efficacy studies, as well as real-world data on vaccine effectiveness and the impact of virus variants of concern. Where they have been deployed in a high proportion of the adult population, the currently approved vaccines have been extremely effective in preventing COVID-19, particularly severe disease. Nonetheless, there are still significant challenges in ensuring equitable vaccine access around the globe and lessons that can be learned for controlling this pandemic and for the next pandemic. This Progress article provides an update on the COVID-19 vaccine effort in the light of ongoing vaccine efficacy studies and real-world data on vaccine effectiveness, including the impact of virus variants of concern and challenges for global deployment.
Subfields: Health, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/b8b7b90263b1168d9466feb99ce2ce1efa7514b3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- A. M. Mobarak
- Edward Miguel
- Esther Duflo
- Abhijit Banerjee
- Nathan Nunn
- Patricia Justino
- Andrés Moya
- Solomon Hsiang
Citations in the corpus
- mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant (2021, neutral): “, 2021), it is unclear whether this correlation will be maintained among boosted individuals and for highly mutated variants like Omicron (Bajema et al., 2021; Lopez Bernal et al., 2021; Tregoning et al., 2021).”
- The Economics of the COVID-19 Pandemic in Poor Countries (2021, background): “The main cause of this drop is the mass deployment of vaccines (Tregoning et al. 2021), beginning in early 2021 (Figures 2 and 3, Panel C).”